购物车
- 全部删除
- 您的购物车当前为空
AGI-14100 是一种新型且可口服的 mIDH1 抑制剂。AGI-14100 用于治疗原发性人类髓性白血病。
为众多的药物研发团队赋能,
让新药发现更简单!
AGI-14100 是一种新型且可口服的 mIDH1 抑制剂。AGI-14100 用于治疗原发性人类髓性白血病。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 2,350 | 现货 | |
5 mg | ¥ 5,630 | 现货 | |
10 mg | ¥ 7,790 | 现货 | |
25 mg | ¥ 11,200 | 现货 | |
50 mg | ¥ 13,800 | 现货 | |
100 mg | ¥ 17,500 | 现货 | |
500 mg | ¥ 38,500 | 现货 |
产品描述 | AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia. |
靶点活性 | HT1080 (chondrosarcoma cell lines):1 nM, IDH1-R132H homodimer (mutation):6 nM |
体内活性 | AGI-14100 (50 mg/kg; oral; single; female nude BALB/c mice) inhibition robust tumor 2-HG was achieved 12 hours post-dose demonstrating desirable in vivo results.[1] AGI-14100 had decent oral pharmacokinetics (PK) properties in rats (F =44 %), dogs (F =18 %), and cynomolgus monkeys (F =43 %).[1] |
别名 | AGI 14100 |
分子量 | 599.96 |
分子式 | C29H22ClF4N5O3 |
CAS No. | 1448346-43-7 |
Smiles | N([C@H](C(NC1CC(F)(F)C1)=O)C2=C(Cl)C=CC=C2)(C(=O)[C@H]3N(C(=O)CC3)C4=CC(C#N)=CC=N4)C5=CC(F)=CC(F)=C5 |
密度 | 1.51 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (83.34 mM) | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容